Latest filings (excl ownership)
8-K
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Forward-Looking Statements Disclaimer
12 Apr 24
NT 10-K
Notice of late annual filing
18 Mar 24
8-K
Departure of Directors or Certain Officers
8 Mar 24
8-K
Entry into a Material Definitive Agreement
1 Mar 24
8-K
Cost Associated with Exit or Disposal Activities
29 Feb 24
8-K
Other Events
13 Feb 24
8-K
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
18 Jan 24
8-K
Entry into a Material Definitive Agreement
16 Jan 24
8-K/A
Departure of Directors or Certain Officers
22 Dec 23
8-K
Results of Operations and Financial Condition
15 Dec 23
8-K
Regulation FD Disclosure
6 Dec 23
8-K
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
29 Nov 23
8-K
Eagle Pharmaceuticals Announces Management Change
29 Nov 23
NT 10-Q
Notice of late quarterly filing
9 Nov 23
8-K
Eagle Delays Third Quarter 2023 Results and Conference Call
9 Nov 23
8-K
Regulation FD Disclosure
24 Oct 23
8-K
Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS
23 Oct 23
8-K
Regulation FD Disclosure
27 Sep 23
8-K
Regulation FD Disclosure
7 Sep 23
8-K
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of
29 Aug 23
8-K
Regulation FD Disclosure
17 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Eagle Pharmaceuticals Reports Second Quarter 2023 Results
8 Aug 23
8-K
Regulation FD Disclosure
31 Jul 23
8-K
Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past half century1
24 Jul 23
8-K
Regulation FD Disclosure
18 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
30 Jun 23
8-K
Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance
15 Jun 23
8-K
Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease
14 Jun 23
8-K
Termination of a Material Definitive Agreement
9 Jun 23
8-K
Regulation FD Disclosure
6 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Eagle Pharmaceuticals Reports First Quarter 2023 Results
9 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
8-K
Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®1 (remimazolam for injection) from CMS
1 May 23
8-K
Entry into a Material Definitive Agreement
10 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
Latest ownership filings
SC 13G/A
Tarriff Scott
18 Mar 24
4
Scott Tarriff
1 Mar 24
4
Brian Joseph Cahill
29 Feb 24
4
Scott Tarriff
29 Feb 24
SC 13D
Graves Michael
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
SC 13G
BRANDES INVESTMENT PARTNERS, LP
12 Feb 24
SC 13G
HIRSCHMAN ORIN
7 Feb 24
4
Brian Joseph Cahill
6 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
22 Jan 24
4
Brian Joseph Cahill
9 Jan 24
4
Scott Tarriff
9 Jan 24
4
Michael Graves
22 Dec 23
4
Brian Joseph Cahill
20 Dec 23
4
Scott Tarriff
3 Nov 23
144
Notice of proposed sale of securities
2 Nov 23
144
Notice of proposed sale of securities
1 Nov 23
4
Michael Graves
31 Oct 23
4
Scott Tarriff
4 Oct 23
144
Notice of proposed sale of securities
3 Oct 23
144
Notice of proposed sale of securities
2 Oct 23
SC 13G/A
BlackRock Inc.
7 Jul 23
4
Scott Tarriff
18 May 23
4
Scott Tarriff
15 May 23
144
Notice of proposed sale of securities
11 May 23
4
STEVEN B RATOFF
9 Mar 23
4
Michael Graves
9 Mar 23
4
Jennifer K. Simpson
9 Mar 23
4
Robert Glenning
9 Mar 23
4
Richard A. Edlin
9 Mar 23
4
LUCIANA BORIO
9 Mar 23
4
Brian Joseph Cahill
2 Mar 23
4
Scott Tarriff
2 Mar 23
SC 13G/A
Tarriff Scott
14 Feb 23
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
4
Brian Joseph Cahill
6 Feb 23
SC 13G/A
STATE STREET CORP
3 Feb 23